STRATA Skin Sciences Preliminary Q2 2024 Revenue Guidance Of $8M-$8.4M Vs $7.42M Est.
STRATA Skin Sciences Preliminary Q2 2024 Revenue Guidance Of $8M-$8.4M Vs $7.42M Est.
STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces preliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consistent with the Company's stated plans of realigning its devices and removing them from underperforming account, the domestic installed base of XTRAC devices declined from 907 at the end of the first quarter of 2024 to 881 at the end of the second quarter of 2024. The domestic installed base of TheraClearX devices continued to grow, rising from 104 at the end of the first quarter of 2024 to 117 at the end of the second quarter of 2024. Cash, cash equivalents, and restricted cash totaled $6.8 million at the end of the second quarter of 2024.
医疗科技公司STRATA Skin Sciences, Inc.（“STRATA”或“公司”）（纳斯达克：SSKN）致力于开发、商业化和推广用于治疗皮肤病的创新产品。宣布2024年第二季度营业收入区间为800万至840万美元。与公司重组设备计划和除去业绩不佳的账户的计划一致，XTRAC设备的美国安装基数从2024年第一季度末的907台下降至2024年第二季末的881台。TheraClearX设备的美国安装基数持续增长，从2024年第一季度末的104台增至2024年第二季末的117台。截至2024年第二季度末，现金、现金等价物和受限现金总计680万美元。